Scarica l'app Stockscreener
1.485
3.57%
-0.055
Pre-mercato:
1.55
0.065
+4.38%
Aldeyra Therapeutics Inc Borsa (ALDX) Ultime notizie
Research Analysts Issue Forecasts for ALDX Q3 Earnings - MarketBeat
AQR Capital Management Expands Aldeyra Therapeutics (ALDX) Stake Despite Steep Stock Decline - GuruFocus
HC Wainwright Has Optimistic Outlook of ALDX FY2030 Earnings - MarketBeat
H.C. Wainwright Maintains Aldeyra Therapeutics(ALDX.US) With Hold Rating, Maintains Target Price $2 - Moomoo
Aldeyra Therapeutics (ALDX) Climbs 8.33% as Biotech Stock Approaches Resistance at $1.64Covered Call Trade - Vinanet
Aldeyra Therapeutics (NASDAQ:ALDX) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Aldeyra Therapeutics (ALDX): AQR Capital discloses 6.22% beneficial ownership stake - Stock Titan
ALDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Connect - ACCESS Newswire
Aldeyra Therapeutics Inc. (ALDX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Aldeyra Therapeutics Inc (ALDX) Stock News Today - TradingKey
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Reach Out - accessnewswire.com
Aldeyra Therapeutics (NASDAQ:ALDX) Announces Quarterly Earnings Results - marketbeat.com
Aldeyra Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Aldeyra Therapeutics, Inc. Q2 2026: Net loss $5.45M, EPS $(0.09) — 10-Q Summary - TradingView
Aldeyra Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
ALDX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review
INVESTOR DEADLINE APPROACHING: Aldeyra Therapeutics (ALDX) Invest - The National Law Review
Aldeyra Therapeutics Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
Aldeyra Therapeutics Leases New Concord Headquarters Space - The Globe and Mail
Aldeyra Therapeutics, Inc. Signs Lease for New Corporate Headquarters in Concord, Massachusetts - marketscreener.com
Aldeyra Therapeutics (NASDAQ: ALDX) leases new Concord headquarters space - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Sahm
Aldeyra Therapeutics Inc (ALDX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BlackRock (ALDX holder) discloses 1.7% Aldeyra Therapeutics stake in amended 13G - Stock Titan
Aldeyra Therapeutics Inc (ALDX) Institutional Confidence - TradingKey
Aldeyra Therapeutics Inc (ALDX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Aldeyra Therapeutics Inc (ALDX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aldeyra Therapeutics Inc (ALDX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aldeyra Therapeutics Inc (ALDX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Aldeyra Therapeutics Inc (ALDX) Cash Flow - TradingKey
Aldeyra Therapeutics, Inc. Revenue Breakdown – NASDAQ:ALDX - TradingView
ALDX|Aldeyra Therapeutics Inc|Price:1.580|Chg%:+0.060 - TradingKey
Aldeyra Therapeutics Inc (ALDX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aldeyra Therapeutics Inc (ALDX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ALDX|Aldeyra Therapeutics Inc|Price:1.520|Chg%:-0.030 - TradingKey
Aldeyra Therapeutics Inc (ALDX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ALDX Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Reach Out - ACCESS Newswire
Price to sales forward of Aldeyra Therapeutics, Inc. – FWB:137 - TradingView
Revenue per share of Aldeyra Therapeutics, Inc. – FWB:137 - TradingView
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Stockholders to Reach Out - ACCESS Newswire
2026-07-19 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Stockholders to Reach Out | NDAQ:ALDX | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Aldeyra Therapeutics to seek Type D meeting with FDA on reproxalap NDA resubmission - TradingView
Aldeyra Therapeutics (NASDAQ: ALDX) advances FDA dialogue on reproxalap NDA - Stock Titan
Understanding the Setup: (ALDX) and Scalable Risk - Stock Traders Daily
ALDX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 - AOL.com
Aldeyra Therapeutics: What Comes Next After Reproxalap's Third CRL (NASDAQ:ALDX) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
ALDX EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 - AOL.com
ALDX Shareholder Alert: Aldeyra Therapeutics, Inc. Securities Class Action LawsuitInvestors Should Contact The Gross Law Firm - AOL.com
Aldeyra Therapeutics (ALDX) Posts Modest Gain Amid Biotech Sector RecoveryReversal Setup Alerts - DonanımHaber
Levicept Ltd (ALDX) Appoints Darlene Deptula-Hicks as CFO Amid P - GuruFocus
Levicept Appoints Darlene Deptula-Hicks as CFO - GlobeNewswire Inc.
Aldeyra Therapeutics Q1 2026 Earnings: Narrower Loss Beats Estimates, Pipeline Progress Remains Key - DonanımHaber
8.37%
0.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):